In addition, while fluorescently tagged anti-EGFR antibodies have been in other studies to guide oncologic surgery in colon cancer, pancreatic cancer, and glioblastoma, these studies lack the power to determine optimal dosing for HNC studies. This evidence concerns the gene EGFR and pancreatic neoplasm.